{"id":"W3025106536","doi":"10.1016/j.msard.2020.102158","title":"Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS","year":2020,"lang":"en","type":"review","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital","funders":"Actelion Pharmaceuticals; Genentech; Bayer Schering; IC Design Education Center; Alkermes; Alexion Pharmaceuticals; Genzyme; Biogen Idec; Patient-Centered Outcomes Research Institute; Celgene; Bayer; Biogen; Bayer HealthCare; Sanofi; Almirall; MedDay Pharmaceuticals; Merck; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; EMD Serono; Novartis; Roche; Pfizer","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Tolerability; Adverse effect; Disease; Fingolimod; Intensive care medicine; Natalizumab; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004145792,0.0008049853,0.003068569,0.0004154542,0.0004463748,0.00007985421,0.000271925,0.0004850625,0.00004752995],"category_scores_gemma":[0.001378067,0.0005725946,0.001247973,0.0006198576,0.0004891553,0.0001940591,0.0003063389,0.0007387372,0.00001020506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001483623,"about_ca_system_score_gemma":0.0003173625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001010394,"about_ca_topic_score_gemma":0.00002323213,"domain_scores_codex":[0.9962792,0.0001478787,0.001326361,0.0009889748,0.0004871174,0.0007704704],"domain_scores_gemma":[0.997323,0.0008291957,0.0006137025,0.0005654808,0.0001525527,0.0005160312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006596741,0.0002486285,0.0009307135,0.0307321,0.001605365,0.00000316366,0.0007350184,0.00001033453,0.0001172033,0.00005525833,0.0004733701,0.9644292],"study_design_scores_gemma":[0.008396778,0.0007527922,0.003781413,0.05170813,0.003376346,0.00000696793,0.0006026619,0.003399292,0.00001195241,0.0002478455,0.9266013,0.001114506],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009966596,0.9927264,0.0001304423,0.0005809003,0.0002125505,0.004467728,0.0004037171,0.0001422713,0.0003393601],"genre_scores_gemma":[0.01609735,0.9814451,0.000835904,0.00004428271,0.0000773003,0.000759301,0.0003499237,0.0002033584,0.0001874221],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9633147,"threshold_uncertainty_score":0.9996725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0781052675865193,"score_gpt":0.3177968576131146,"score_spread":0.2396915900265953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}